“A PHASE 2/3 ADAPTIVE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VX-147 IN SUBIECTS AGED 18 YEARS AND OLDER WITH APOL1-MEDIATED PROTEINURIC KIDNEY DISEASE.”